ID: h-feb25cb4
Hypothesis
STAT3 Epigenetic Priming as Mechanism of Peripheral Cytokine Memory
STAT3 Epigenetic Priming as Mechanism of Peripheral Cytokine Memory.
🧬 IL-6/STAT3/BRD4 axis; target: microglial STAT3 phosphorylation🩺 immunomics🎯 Composite 35%💱 $0.45▲34.8%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 5 oppose
🧪 Overview
STAT3 Epigenetic Priming as Mechanism of Peripheral Cytokine Memory
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Peripheral Cytokine<br/>IL-6 Elevation"]
B["Monocyte STAT3<br/>Phosphorylation Activation"]
C["Epigenetic Priming<br/>BRD4 Reader Complex"]
D["Pro-inflammatory Memory<br/>Training"]
E["Brain Border Macrophage<br/>Reprogramming"]
F["Neuroinflammation<br/>Amplification"]
G["IL-6/STAT3/BRD4 Axis<br/>as Immunomodulation Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"modulates"| B
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix4 supports5 contradicts
Contradicts
CRITICAL MECHANISTIC ERROR: HDAC6 is cytoplasmic deacetylase; does not regulate transcription or chromatin - cited as epigenetic mechanism incorrectly
Contradicts
Trained immunity concept (long-term epigenetic reprogramming) well-established in monocytes/macrophages but applicability to brain microglia remains THEORETICAL
Contradicts
IL-6 can activate neuroprotective pathways via STAT3 in neurons; global inhibition could remove beneficial effects
Contradicts
WP1066 (proposed STAT3 inhibitor) has significant off-target effects and toxicity limiting clinical development
Contradicts
BRD4 super-enhancers demonstrated in macrophages; whether mechanism operates in embryologically distinct microglia is unproven
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — IL-6
No curated PDB or AlphaFold mapping for IL-6 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for IL-6/STAT3/BRD4 axis; target: microglial STAT3 phosphorylation from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for IL-6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↗
Rising
7d Momentum
▲ 1.8%
Volatility
Medium
0.0299
Events (7d)
3
Price History
▲34.8%💾 Resource Usage
LLM Tokens
36,998
$0.1110
Total Cost
$0.1110
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF BRD4 inhibitor JQ1 (50 mg/kg, intraperitoneally) is administered concurrently during peripheral IL-6 priming (100 ng/kg for 5 days), THEN the magnitude of microglial STAT3 phosphorylation elevation | Concurrent BRD4 inhibition will completely abolish the peripheral IL-6-induced priming of microglial STAT3 phosphorylation, reducing p-STAT3 to baseline levels | — no observation — | pending | 0.55 |
| IF adult C57BL/6 mice receive peripheral IL-6 administration (100 ng/kg, intraperitoneally) for 5 consecutive days, THEN isolated brain microglia will show significantly elevated STAT3 phosphorylation | Microglial p-STAT3 levels will remain elevated (≥2-fold above baseline) at 30 days post-IL-6 exposure, demonstrating persistent 'cytokine memory' effect. | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF adult C57BL/6 mice receive peripheral IL-6 administration (100 ng/kg, intraperitoneally) for 5 consecutive days, THEN isolated brain microglia will show significantly elevated STAT3 phosphorylation levels (p<0.05, ≥2-fold increase) compared to vehicle-treated controls at 30 days post-exposure.
Predicted outcome: Microglial p-STAT3 levels will remain elevated (≥2-fold above baseline) at 30 days post-IL-6 exposure, demonstrating persistent 'cytokine memory' effe
Falsification: Microglial STAT3 phosphorylation at 30 days post-exposure shows no significant difference from vehicle controls (<1.2-fold change, p≥0.05), indicating no lasting priming effect.
pendingconf 55%
IF BRD4 inhibitor JQ1 (50 mg/kg, intraperitoneally) is administered concurrently during peripheral IL-6 priming (100 ng/kg for 5 days), THEN the magnitude of microglial STAT3 phosphorylation elevation at 30 days will be indistinguishable from vehicle-only controls (fold change <1.2, p≥0.05), whereas
Predicted outcome: Concurrent BRD4 inhibition will completely abolish the peripheral IL-6-induced priming of microglial STAT3 phosphorylation, reducing p-STAT3 to baseli
Falsification: IL-6 + JQ1 co-treatment still produces ≥1.5-fold elevation in microglial STAT3 phosphorylation at 30 days, demonstrating the mechanism is independent of BRD4-dependent epigenetic priming.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.